Effects of novel lactoferrin peptides on LPS‐induced alveolar bone destruction in a rat model

Abstract

AbstractTo develop novel bovine lactoferrin (bLF) peptides targeting bLF‐tumour necrosis factor (TNF) receptor‐associated factor 6 (TRAF6) binding sites, we identified two peptides that could target bLF‐TRAF6 binding sites using structural analysis. Moreover, another peptide that could bind to the TRAF6 dimerization area was selected from the bLF sequence. The effects of each peptide on cytokine expression in lipopolysaccharide (LPS)‐stimulated osteoblasts (ST2) and on osteoclastogenesis were examined using an LPS‐treated co‐culture of primary bone marrow cells (BMCs) with ST2 cells and a single culture of osteoclast precursor cells (RAW‐D) treated with soluble receptor activator of NF‐κB ligand. Finally, the effectiveness of these peptides against LPS‐induced alveolar bone destruction was assessed. Two of the three peptides significantly suppressed LPS‐induced TNF‐α and interleukin‐1β expression in ST2 cells. Additionally, these peptides inhibited and reversed LPS‐induced receptor activator of NF‐κB ligand (RANKL) upregulation and osteoprotegerin (OPG) downregulation, respectively. Furthermore, both peptides significantly reduced LPS‐induced osteoclastogenesis in the BMC‐ST2 co‐culture and RANKL‐induced osteoclastogenesis in RAW‐D cells. In vivo, topical application of these peptides significantly reduced the osteoclast number by downregulating RANKL and upregulating OPG in the periodontal ligament. It is indicated that the novel bLF peptides can be used to treat periodontitis‐associated bone destruction.